{"pmid":32193904,"title":"Drive-Through Screening Center for COVID-19: a Safe and Efficient Screening System against Massive Community Outbreak.","text":["Drive-Through Screening Center for COVID-19: a Safe and Efficient Screening System against Massive Community Outbreak.","As the coronavirus disease 2019 (COVID-19) outbreak is ongoing, the number of individuals to be tested for COVID-19 is rapidly increasing. For safe and efficient screening for COVID-19, drive-through (DT) screening centers have been designed and implemented in Korea. Herein, we present the overall concept, advantages, and limitations of the COVID-19 DT screening centers. The steps of the DT centers include registration, examination, specimen collection, and instructions. The entire service takes about 10 minutes for one testee without leaving his or her cars. Increased testing capacity over 100 tests per day and prevention of cross-infection between testees in the waiting space are the major advantages, while protection of staff from the outdoor atmosphere is challenging. It could be implemented in other countries to cope with the global COVID-19 outbreak and transformed according to their own situations.","J Korean Med Sci","Kwon, Ki Tae","Ko, Jae Hoon","Shin, Heejun","Sung, Minki","Kim, Jin Yong","32193904"],"abstract":["As the coronavirus disease 2019 (COVID-19) outbreak is ongoing, the number of individuals to be tested for COVID-19 is rapidly increasing. For safe and efficient screening for COVID-19, drive-through (DT) screening centers have been designed and implemented in Korea. Herein, we present the overall concept, advantages, and limitations of the COVID-19 DT screening centers. The steps of the DT centers include registration, examination, specimen collection, and instructions. The entire service takes about 10 minutes for one testee without leaving his or her cars. Increased testing capacity over 100 tests per day and prevention of cross-infection between testees in the waiting space are the major advantages, while protection of staff from the outdoor atmosphere is challenging. It could be implemented in other countries to cope with the global COVID-19 outbreak and transformed according to their own situations."],"journal":"J Korean Med Sci","authors":["Kwon, Ki Tae","Ko, Jae Hoon","Shin, Heejun","Sung, Minki","Kim, Jin Yong"],"date":"2020-03-21T11:00:00Z","year":2020,"_id":"32193904","week":"202012|Mar 16 - Mar 22","doi":"10.3346/jkms.2020.35.e123","keywords":["COVID-19","Drive-through","Outbreak","SARS-CoV-2","Screening"],"source":"PubMed","locations":["South Korea"],"countries":["Korea, Republic of"],"countries_codes":["KOR|Korea, Republic of"],"topics":["Diagnosis"],"weight":1,"_version_":1661818360736776192,"score":6.891626,"similar":[{"pmid":32165854,"pmcid":"PMC7061485","title":"Coronavirus disease-2019: is fever an adequate screening for the returning travelers?","text":["Coronavirus disease-2019: is fever an adequate screening for the returning travelers?","On Thursday, 30 January 2020, World Health Organization declared Coronavirus disease-2019 (COVID-2019) a Public Health Emergency of International Concern. Since its identification in late December 2019 in Wuhan, Hubei Province, People's Republic of China, the number of cases imported into other countries is increasing, and the epidemiological map is changing rapidly. On the other hand, body temperature screening (fever) is the major test performed at points of entry, i.e., airports, in the returning travelers in most of the countries with limited resources. However, the recent report on asymptomatic contact transmission of COVID-19 and travelers who passed the symptoms-based screening and tested positive for COVID-19 using reverse transcription polymerase chain reaction (RT-PCR) challenges this approach as body temperature screening may miss travelers incubating the disease or travelers concealing fever during travel. On this note, travel restrictions to and from high risk areas and/or 14 days quarantine of travelers coming from high risk areas are recommended to prevent possible importation of COVID-19. Currently, RT-PCR is a reliable test in detecting both symptomatic and asymptomatic COVID-19.","Trop Med Health","Bwire, George M","Paulo, Linda S","32165854"],"abstract":["On Thursday, 30 January 2020, World Health Organization declared Coronavirus disease-2019 (COVID-2019) a Public Health Emergency of International Concern. Since its identification in late December 2019 in Wuhan, Hubei Province, People's Republic of China, the number of cases imported into other countries is increasing, and the epidemiological map is changing rapidly. On the other hand, body temperature screening (fever) is the major test performed at points of entry, i.e., airports, in the returning travelers in most of the countries with limited resources. However, the recent report on asymptomatic contact transmission of COVID-19 and travelers who passed the symptoms-based screening and tested positive for COVID-19 using reverse transcription polymerase chain reaction (RT-PCR) challenges this approach as body temperature screening may miss travelers incubating the disease or travelers concealing fever during travel. On this note, travel restrictions to and from high risk areas and/or 14 days quarantine of travelers coming from high risk areas are recommended to prevent possible importation of COVID-19. Currently, RT-PCR is a reliable test in detecting both symptomatic and asymptomatic COVID-19."],"journal":"Trop Med Health","authors":["Bwire, George M","Paulo, Linda S"],"date":"2020-03-14T11:00:00Z","year":2020,"_id":"32165854","week":"202011|Mar 09 - Mar 15","doi":"10.1186/s41182-020-00201-2","keywords":["COVID-19","Fever","Returning travelers","Temperature screening"],"source":"PubMed","locations":["Wuhan","Hubei"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Diagnosis"],"weight":1,"_version_":1661359647940935681,"score":167.44565},{"pmid":32156101,"title":"Development of a Laboratory-safe and Low-cost Detection Protocol for SARS-CoV-2 of the Coronavirus Disease 2019 (COVID-19).","text":["Development of a Laboratory-safe and Low-cost Detection Protocol for SARS-CoV-2 of the Coronavirus Disease 2019 (COVID-19).","The severe acute respiratory coronavirus 2 (SARS-CoV-2), which emerged in December 2019 in Wuhan, China, has spread rapidly to over a dozen countries. Especially, the spike of case numbers in South Korea sparks pandemic worries. This virus is reported to spread mainly through personto- person contact via respiratory droplets generated by coughing and sneezing, or possibly through surface contaminated by people coughing or sneezing on them. More critically, there have been reports about the possibility of this virus to transmit even before a virus-carrying person to show symptoms. Therefore, a low-cost, easy-access protocol for early detection of this virus is desperately needed. Here, we have established a real-time reverse-transcription PCR (rtPCR)-based assay protocol composed of easy specimen self-collection from a subject via pharyngeal swab, Trizolbased RNA purification, and SYBR Green-based rtPCR. This protocol shows an accuracy and sensitivity limit of 1-10 virus particles as we tested with a known lentivirus. The cost for each sample is estimated to be less than 15 US dollars. Overall time it takes for an entire protocol is estimated to be less than 4 hours. We propose a cost-effective, quick-and-easy method for early detection of SARS-CoV-2 at any conventional Biosafety Level II laboratories that are equipped with a rtPCR machine. Our newly developed protocol should be helpful for a first-hand screening of the asymptomatic virus-carriers for further prevention of transmission and early intervention and treatment for the rapidly propagating virus.","Exp Neurobiol","Won, Joungha","Lee, Solji","Park, Myungsun","Kim, Tai Young","Park, Mingu Gordon","Choi, Byung Yoon","Kim, Dongwan","Chang, Hyeshik","Kim, V Narry","Lee, C Justin","32156101"],"abstract":["The severe acute respiratory coronavirus 2 (SARS-CoV-2), which emerged in December 2019 in Wuhan, China, has spread rapidly to over a dozen countries. Especially, the spike of case numbers in South Korea sparks pandemic worries. This virus is reported to spread mainly through personto- person contact via respiratory droplets generated by coughing and sneezing, or possibly through surface contaminated by people coughing or sneezing on them. More critically, there have been reports about the possibility of this virus to transmit even before a virus-carrying person to show symptoms. Therefore, a low-cost, easy-access protocol for early detection of this virus is desperately needed. Here, we have established a real-time reverse-transcription PCR (rtPCR)-based assay protocol composed of easy specimen self-collection from a subject via pharyngeal swab, Trizolbased RNA purification, and SYBR Green-based rtPCR. This protocol shows an accuracy and sensitivity limit of 1-10 virus particles as we tested with a known lentivirus. The cost for each sample is estimated to be less than 15 US dollars. Overall time it takes for an entire protocol is estimated to be less than 4 hours. We propose a cost-effective, quick-and-easy method for early detection of SARS-CoV-2 at any conventional Biosafety Level II laboratories that are equipped with a rtPCR machine. Our newly developed protocol should be helpful for a first-hand screening of the asymptomatic virus-carriers for further prevention of transmission and early intervention and treatment for the rapidly propagating virus."],"journal":"Exp Neurobiol","authors":["Won, Joungha","Lee, Solji","Park, Myungsun","Kim, Tai Young","Park, Mingu Gordon","Choi, Byung Yoon","Kim, Dongwan","Chang, Hyeshik","Kim, V Narry","Lee, C Justin"],"date":"2020-03-12T11:00:00Z","year":2020,"_id":"32156101","week":"202011|Mar 09 - Mar 15","doi":"10.5607/en20009","keywords":["COVID-19","Communicable diseases","Coronavirus","Diagnostic techniques and procedures","Emerging","Infectious disease","SARS virus"],"source":"PubMed","locations":["Wuhan","South Korea","China"],"countries":["Korea, Republic of","China"],"countries_codes":["KOR|Korea, Republic of","CHN|China"],"topics":["Diagnosis"],"weight":1,"_version_":1661359647859146754,"score":164.61725},{"pmid":32133832,"title":"[Potential false-positive rate among the 'asymptomatic infected individuals' in close contacts of COVID-19 patients].","text":["[Potential false-positive rate among the 'asymptomatic infected individuals' in close contacts of COVID-19 patients].","Objective: As the prevention and control of COVID-19continues to advance, the active nucleic acid test screening in the close contacts of the patients has been carrying out in many parts of China. However, the false-positive rate of positive results in the screening has not been reported up to now. But to clearify the false-positive rate during screening is important in COVID-19 control and prevention. Methods: Point values and reasonable ranges of the indicators which impact the false-positive rate of positive results were estimated based on the information available to us at present. The false-positive rate of positive results in the active screening was deduced, and univariate and multivariate-probabilistic sensitivity analyses were performed to understand the robustness of the findings. Results: When the infection rate of the close contacts and the sensitivity and specificity of reported results were taken as the point estimates, the positive predictive value of the active screening was only 19.67%, in contrast, the false-positive rate of positive results was 80.33%. The multivariate-probabilistic sensitivity analysis results supported the base-case findings, with a 75% probability for the false-positive rate of positive results over 47%. Conclusions: In the close contacts of COVID-19 patients, nearly half or even more of the 'asymptomatic infected individuals' reported in the active nucleic acid test screening might be false positives.","Zhonghua Liu Xing Bing Xue Za Zhi","Zhuang, G H","Shen, M W","Zeng, L X","Mi, B B","Chen, F Y","Liu, W J","Pei, L L","Qi, X","Li, C","32133832"],"abstract":["Objective: As the prevention and control of COVID-19continues to advance, the active nucleic acid test screening in the close contacts of the patients has been carrying out in many parts of China. However, the false-positive rate of positive results in the screening has not been reported up to now. But to clearify the false-positive rate during screening is important in COVID-19 control and prevention. Methods: Point values and reasonable ranges of the indicators which impact the false-positive rate of positive results were estimated based on the information available to us at present. The false-positive rate of positive results in the active screening was deduced, and univariate and multivariate-probabilistic sensitivity analyses were performed to understand the robustness of the findings. Results: When the infection rate of the close contacts and the sensitivity and specificity of reported results were taken as the point estimates, the positive predictive value of the active screening was only 19.67%, in contrast, the false-positive rate of positive results was 80.33%. The multivariate-probabilistic sensitivity analysis results supported the base-case findings, with a 75% probability for the false-positive rate of positive results over 47%. Conclusions: In the close contacts of COVID-19 patients, nearly half or even more of the 'asymptomatic infected individuals' reported in the active nucleic acid test screening might be false positives."],"journal":"Zhonghua Liu Xing Bing Xue Za Zhi","authors":["Zhuang, G H","Shen, M W","Zeng, L X","Mi, B B","Chen, F Y","Liu, W J","Pei, L L","Qi, X","Li, C"],"date":"2020-03-06T11:00:00Z","year":2020,"_id":"32133832","week":"202010|Mar 02 - Mar 08","doi":"10.3760/cma.j.cn112338-20200221-00144","keywords":["COVID-19","Close contacts","False-positive","Nucleic acid test","Screening"],"source":"PubMed","locations":["China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Diagnosis"],"weight":1,"_version_":1661359647725977600,"score":135.35497},{"pmid":32113846,"title":"In silico screening of Chinese herbal medicines with the potential to directly inhibit 2019 novel coronavirus.","text":["In silico screening of Chinese herbal medicines with the potential to directly inhibit 2019 novel coronavirus.","OBJECTIVE: In this study we execute a rational screen to identify Chinese medical herbs that are commonly used in treating viral respiratory infections and also contain compounds that might directly inhibit 2019 novel coronavirus (2019-nCoV), an ongoing novel coronavirus that causes pneumonia. METHODS: There were two main steps in the screening process. In the first step we conducted a literature search for natural compounds that had been biologically confirmed as against sever acute respiratory syndrome coronavirus or Middle East respiratory syndrome coronavirus. Resulting compounds were cross-checked for listing in the Traditional Chinese Medicine Systems Pharmacology Database. Compounds meeting both requirements were subjected to absorption, distribution, metabolism and excretion (ADME) evaluation to verify that oral administration would be effective. Next, a docking analysis was used to test whether the compound had the potential for direct 2019-nCoV protein interaction. In the second step we searched Chinese herbal databases to identify plants containing the selected compounds. Plants containing 2 or more of the compounds identified in our screen were then checked against the catalogue for classic herbal usage. Finally, network pharmacology analysis was used to predict the general in vivo effects of each selected herb. RESULTS: Of the natural compounds screened, 13 that exist in traditional Chinese medicines were also found to have potential anti-2019-nCoV activity. Further, 125 Chinese herbs were found to contain 2 or more of these 13 compounds. Of these 125 herbs, 26 are classically catalogued as treating viral respiratory infections. Network pharmacology analysis predicted that the general in vivo roles of these 26 herbal plants were related to regulating viral infection, immune/inflammation reactions and hypoxia response. CONCLUSION: Chinese herbal treatments classically used for treating viral respiratory infection might contain direct anti-2019-nCoV compounds.","J Integr Med","Zhang, Deng-Hai","Wu, Kun-Lun","Zhang, Xue","Deng, Sheng-Qiong","Peng, Bin","32113846"],"abstract":["OBJECTIVE: In this study we execute a rational screen to identify Chinese medical herbs that are commonly used in treating viral respiratory infections and also contain compounds that might directly inhibit 2019 novel coronavirus (2019-nCoV), an ongoing novel coronavirus that causes pneumonia. METHODS: There were two main steps in the screening process. In the first step we conducted a literature search for natural compounds that had been biologically confirmed as against sever acute respiratory syndrome coronavirus or Middle East respiratory syndrome coronavirus. Resulting compounds were cross-checked for listing in the Traditional Chinese Medicine Systems Pharmacology Database. Compounds meeting both requirements were subjected to absorption, distribution, metabolism and excretion (ADME) evaluation to verify that oral administration would be effective. Next, a docking analysis was used to test whether the compound had the potential for direct 2019-nCoV protein interaction. In the second step we searched Chinese herbal databases to identify plants containing the selected compounds. Plants containing 2 or more of the compounds identified in our screen were then checked against the catalogue for classic herbal usage. Finally, network pharmacology analysis was used to predict the general in vivo effects of each selected herb. RESULTS: Of the natural compounds screened, 13 that exist in traditional Chinese medicines were also found to have potential anti-2019-nCoV activity. Further, 125 Chinese herbs were found to contain 2 or more of these 13 compounds. Of these 125 herbs, 26 are classically catalogued as treating viral respiratory infections. Network pharmacology analysis predicted that the general in vivo roles of these 26 herbal plants were related to regulating viral infection, immune/inflammation reactions and hypoxia response. CONCLUSION: Chinese herbal treatments classically used for treating viral respiratory infection might contain direct anti-2019-nCoV compounds."],"journal":"J Integr Med","authors":["Zhang, Deng-Hai","Wu, Kun-Lun","Zhang, Xue","Deng, Sheng-Qiong","Peng, Bin"],"date":"2020-03-02T11:00:00Z","year":2020,"_id":"32113846","week":"202010|Mar 02 - Mar 08","doi":"10.1016/j.joim.2020.02.005","keywords":["2019-nCoV","Chinese herbal","Drugs","Molecular docking","Natural compounds","Network pharmacology","Pneumonia","Wuhan coronavirus"],"source":"PubMed","locations":["Chinese","vivo"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Treatment"],"weight":1,"_version_":1661359647560302592,"score":113.48571},{"pmid":32091395,"pmcid":"PMC7060038","title":"Estimated effectiveness of symptom and risk screening to prevent the spread of COVID-19.","text":["Estimated effectiveness of symptom and risk screening to prevent the spread of COVID-19.","Traveller screening is being used to limit further spread of COVID-19 following its recent emergence, and symptom screening has become a ubiquitous tool in the global response. Previously, we developed a mathematical model to understand factors governing the effectiveness of traveller screening to prevent spread of emerging pathogens (Gostic et al., 2015). Here, we estimate the impact of different screening programs given current knowledge of key COVID-19 life history and epidemiological parameters. Even under best-case assumptions, we estimate that screening will miss more than half of infected people. Breaking down the factors leading to screening successes and failures, we find that most cases missed by screening are fundamentally undetectable, because they have not yet developed symptoms and are unaware they were exposed. Our work underscores the need for measures to limit transmission by individuals who become ill after being missed by a screening program. These findings can support evidence-based policy to combat the spread of COVID-19, and prospective planning to mitigate future emerging pathogens.","Elife","Gostic, Katelyn","Gomez, Ana Cr","Mummah, Riley O","Kucharski, Adam J","Lloyd-Smith, James O","32091395"],"abstract":["Traveller screening is being used to limit further spread of COVID-19 following its recent emergence, and symptom screening has become a ubiquitous tool in the global response. Previously, we developed a mathematical model to understand factors governing the effectiveness of traveller screening to prevent spread of emerging pathogens (Gostic et al., 2015). Here, we estimate the impact of different screening programs given current knowledge of key COVID-19 life history and epidemiological parameters. Even under best-case assumptions, we estimate that screening will miss more than half of infected people. Breaking down the factors leading to screening successes and failures, we find that most cases missed by screening are fundamentally undetectable, because they have not yet developed symptoms and are unaware they were exposed. Our work underscores the need for measures to limit transmission by individuals who become ill after being missed by a screening program. These findings can support evidence-based policy to combat the spread of COVID-19, and prospective planning to mitigate future emerging pathogens."],"journal":"Elife","authors":["Gostic, Katelyn","Gomez, Ana Cr","Mummah, Riley O","Kucharski, Adam J","Lloyd-Smith, James O"],"date":"2020-02-25T11:00:00Z","year":2020,"_id":"32091395","week":"20209|Feb 24 - Mar 01","doi":"10.7554/eLife.55570","keywords":["COVID-19","SARS-CoV-2","emerging infectious disease","epidemic containment","epidemic control","epidemiology","global health","human","travel screening","virus"],"source":"PubMed","topics":["Treatment"],"weight":1,"_version_":1661359647426084865,"score":113.04878}]}